1. NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017.
- Author
-
Nabors LB, Portnow J, Ammirati M, Baehring J, Brem H, Butowski N, Fenstermaker RA, Forsyth P, Hattangadi-Gluth J, Holdhoff M, Howard S, Junck L, Kaley T, Kumthekar P, Loeffler JS, Moots PL, Mrugala MM, Nagpal S, Pandey M, Parney I, Peters K, Puduvalli VK, Ragsdale J, Rockhill J, Rogers L, Rusthoven C, Shonka N, Shrieve DC, Sills AK, Swinnen LJ, Tsien C, Weiss S, Wen PY, Willmarth N, Bergman MA, and Engh A
- Subjects
- Antineoplastic Combined Chemotherapy Protocols standards, Central Nervous System Neoplasms classification, Central Nervous System Neoplasms pathology, Central Nervous System Neoplasms therapy, Combined Modality Therapy methods, Combined Modality Therapy standards, Glioma classification, Glioma pathology, Glioma therapy, Humans, Neoadjuvant Therapy methods, Neoadjuvant Therapy standards, Neoplasm Grading, Prognosis, Radiotherapy methods, Radiotherapy standards, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Biomarkers, Tumor analysis, Central Nervous System Neoplasms diagnosis, Glioma diagnosis, Nervous System pathology
- Abstract
For many years, the diagnosis and classification of gliomas have been based on histology. Although studies including large populations of patients demonstrated the prognostic value of histologic phenotype, variability in outcomes within histologic groups limited the utility of this system. Nonetheless, histology was the only proven and widely accessible tool available at the time, thus it was used for clinical trial entry criteria, and therefore determined the recommended treatment options. Research to identify molecular changes that underlie glioma progression has led to the discovery of molecular features that have greater diagnostic and prognostic value than histology. Analyses of these molecular markers across populations from randomized clinical trials have shown that some of these markers are also predictive of response to specific types of treatment, which has prompted significant changes to the recommended treatment options for grade III (anaplastic) gliomas., (Copyright © 2017 by the National Comprehensive Cancer Network.)
- Published
- 2017
- Full Text
- View/download PDF